Financial Results : Jamjoom Pharma profit rises 30% to SAR 395.7M in 9M 2025; Q3 at SAR 106.7M

Jamjoom Pharma profit rises 30% to SAR 395.7M in 9M 2025; Q3 at SAR 106.7M

23/10/2025 Argaam Exclusive

View other reports

 Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) reported a net profit of SAR 395.7 million for the first nine months of 2025, an increase of 30% from SAR 304.9 million in the year-earlier period.


Financials (M)

Item 9m 2024 9m 2025 Change‬
Revenues 1,058.77 1,196.06 13.0 %
Gross Income 661.99 752.18 13.6 %
Operating Income 327.08 403.45 23.3 %
Net Income 304.92 395.73 29.8 %
Average Shares 70.00 70.00 -
Earnings Per Share before unusual items (Riyals) 4.36 5.65 29.8 %
EPS (Riyal) 4.36 5.65 29.8 %

Revenue rose 13% year-on-year (YoY) during 9M 2025, on improved operational efficiency, supported by the company’s focus on high-value strategic commercial products, core therapeutic areas, and targeted expansion in key markets.

 

The company noted the absence of high finance costs, along with a one-off exceptional income recognized during the period, along with a decrease in expected credit loss provisions, which helped offset the decline in income from its joint venture.

 

Q3 2025 net profit rose 12% YoY to SAR 106.7 million on a 4.5% increase in revenue compared to Q3 2024. The rise in revenue was driven by higher volumes in key markets, improved operational efficiency, new commercial products, price adjustments, and continued momentum in high-value therapeutic areas. The growth was further supported by lower provisions and higher net finance income.



Current Quarter Comparison (M)

Compared With The
Item Q3 2024 Q3 2025 Change‬
Revenues 327.58 342.31 4.5 %
Gross Income 194.41 208.54 7.3 %
Operating Income 94.84 109.92 15.9 %
Net Income 94.99 106.67 12.3 %
Average Shares 70.00 70.00 -
Earnings Per Share before unusual items (Riyal) 1.36 1.52 12.3 %
EPS (Riyal) 1.36 1.52 12.3 %

On a sequential basis, net earnings fell 19.2% from SAR 132 million in Q2 2025.

 

Total shareholders’ equity, no minority interest, reached SAR 1.65 billion by Sept. 30, 2025, compared to SAR 1.44 billion in the year-earlier period.

Attached document:

 

 

View More Financial Results

 

Kindly, you can view the full report by subscribing to the

The report contains the details of the financial statements, The most important financial indicators, Historical information, Charts, and Forecasts of experts.

Contact Us (+966)-92000-7759

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.